Experts at the 2025 Clinical Trial Supply New England conference will discuss strategies for optimising clinical supply ...

The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

Latigo has secured $150m in a Series funding round, which will be used to further the development of its Nav1.8 inhibitors.

While China has become a key country for global clinical trials, navigating regulatory complexities and ensuring data ...

Taiho Pharmaceutical has agreed to acquire Swiss-based antibody-drug-conjugate (ADC) specialist Araris Biotech for up to ...

Azurity Pharmaceuticals has acquired Covis Group from existing investors, making the latter a wholly owned subsidiary.

The EC has granted expanded approval to BMS' Breyanzi, to treat adults with relapsed or refractory follicular lymphoma (FL).

The EMA warns of products being sold as dendritic cell therapies with little evidence, but high health risks, in the European ...

Boehringer Ingelheim and Sweden-based Salipro Biotech have entered a research and licence agreement for drug targets' ...

Halo Pharmaceutical is a privately owned full service FDA, BLA and DEA (Schedule II-V) compliant CDMO, headquartered in ...

The venture aims to advance MeiraGTx’s Parkinson’s gene therapy through Phase III trials with up to $430m in funding from ...